Navidea Biopharmaceuticals is a biopharmaceutical company engaged in developing and commercializing precision diagnostics and radiopharmaceutical agents. The company is actively developing four radiopharmaceutical agent platforms: Lymphoseek, NAV4694, NAV5001 and RIGScan. The company aims to deliver superior growth and shareholder return by bringing novel radiopharmaceutical agents to market and by advancing its pipeline through selective acquisitions, worldwide partnering and commercialization efforts. For more information, visit the company’s Web site at www.navidea.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: